公开(公告)号：US20170298131A1

公开(公告)日：2017-10-19

申请号：US15511792

申请日：2015-09-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/00

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20190322744A1

公开(公告)日：2019-10-24

申请号：US16448016

申请日：2019-06-21

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE SOULAS ,  NICOLAI WAGTMANN

IPC: C07K16/28

Abstract: The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

公开(公告)号：US20240368281A1

公开(公告)日：2024-11-07

申请号：US18772517

申请日：2024-07-15

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20170313773A1

公开(公告)日：2017-11-02

申请号：US15521401

申请日：2015-10-23

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CAROLINE SOULAS ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to HLA-E as a tumor escape mechanism in head and neck cancer. The disclosure relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

公开(公告)号：US20210238285A1

公开(公告)日：2021-08-05

申请号：US17225160

申请日：2021-04-08

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

公开(公告)号：US20200299383A1

公开(公告)日：2020-09-24

申请号：US16894937

申请日：2020-06-08

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  CAROLINE SOULAS ,  NICOLAÏ WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

Abstract: The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.